RE:RE:RE:RE:The state of the base business is strong. Rev $4.273 millionGood results but digitel might be right about avenanthramides stock up. Still, while I realise it is long way off to trial end, I'd be more interested in the opening remark in the NR about beta glucan alone (as first confirmed in february.) When one looks at all the hype around Amarin and HLS with the Cad rights for that company's Vascepa (though patent challenges remain in USA on that), then if beta glucan ALONE (or even in combination with statins) is proven to be therapy, then it will be a blockbuster. And if it is good, then earlier results on beta glucan alone would be great.
Held CZO for ages. Always wth hope PGX would derive significant revenue.